Targeted treatment of chronic myeloid leukemia: role of imatinib

被引：0

作者：

Tamascar, Ila ^{[1
]}

Ramanarayanan, Jeyanthi ^{[1
]}

机构：

[1] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA

来源：

ONCOTARGETS AND THERAPY | 2009年 / 2卷

关键词：

BCR-ABL; imatinib; tyrosine kinase inhibitors; leukemia; CML; CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; LATE CHRONIC PHASE; CHROMOSOMAL-ABNORMALITIES; CYTOGENETIC RESPONSES; MESYLATE THERAPY; NEGATIVE CELLS; OCT-1; ACTIVITY; BLAST CRISIS; FOLLOW-UP;

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of pleuripotent hematopoetic stem cells. The incidence of CML is 1 to 2 cases per 100,000 people per year; in the Western Hemisphere, CML accounts for 15% of leukemias in adults. Discovery of the specific karyotypic abnormality of the Philadelphia (Ph) chromosome in the pathogenesis of CML has led to a better understanding of the disease and hence to an advancement of targeted therapeutics. Availability of imatinib as an accepted targeted therapy in newly diagnosed patients has changed the treatment paradigm in CML. The majority of CML patients in chronic phase achieve excellent and durable responses with standard-dose imatinib. Mechanisms of primary and secondary resistance to imatinib in CML have been extensively studied and newer tyrosine kinase inhibitors are now being evaluated for clinical use. It is important that at any time the CML treatment and response remain optimal and thus patients on imatinib require continuous monitoring for early detection of resistance. This review will discuss the treatment and guidelines for monitoring CML patients in the imatinib era.

引用

页码：63 / 71

页数：9

共 40 条

[1] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[2] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[3]

Cervantes F, 2003, HAEMATOLOGICA, V88, P1117

[4]

CORTES J, 2000, 13 C EUR HEM ASS

[5] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].

DALEY, GQ ;

VANETTEN, RA ;

BALTIMORE, D .

SCIENCE, 1990, 247 (4944) :824-830

[6] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

[7] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[8] Chronic myelogenous leukemia: Biology and therapy [J].

Faderl, S ;

Talpaz, M ;

Estrov, Z ;

Kantarjian, HM .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) :207-219

[9] Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [J].

Huntly, BJP ;

Reid, AG ;

Bench, AJ ;

Campbell, LJ ;

Telford, N ;

Shepherd, P ;

Szer, J ;

Prince, HM ;

Turner, P ;

Grace, C ;

Nacheva, EP ;

Green, AR .

BLOOD, 2001, 98 (06) :1732-1738

[10] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate [J].

Jabbour, E. ;

Kantarjian, H. ;

Jones, D. ;

Talpaz, M. ;

Bekele, N. ;

O'Brien, S. ;

Zhou, X. ;

Luthra, R. ;

Garcia-Manero, G. ;

Giles, F. ;

Rios, M. B. ;

Verstovsek, S. ;

Cortes, J. .

LEUKEMIA, 2006, 20 (10) :1767-1773

← 1 2 3 4 →